<DOC>
	<DOCNO>NCT01938599</DOCNO>
	<brief_summary>To compare safety efficacy profile AM001 Cream vehicle treatment plaque psoriasis .</brief_summary>
	<brief_title>Study Comparing AM001 Cream Vehicle Treatment Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Skin Diseases , Papulosquamous</mesh_term>
	<criteria>1 . Subjects must provide Institutional Review Board ( IRB ) approve write informed consent . 2 . Subjects must male female , least 18 year age . 3 . Subjects definite diagnosis plaque psoriasis clinically active ( least 3 month ) , involve least 3 % 20 % body surface area ( include scalp , face , hand , foot , intertriginous area ) . 4 . Subjects Investigator 's Global Assessment ( IGA ) disease severity least moderate severity ( score ≥ 3 ) overall assessment . 5 . Subjects minimum plaque elevation least moderate severity ( PASI grade ≥ 3 ) target lesion site . 6 . If female childbearing potential , subject must negative urine pregnancy test , must use acceptable form birth control least two month prior Screening willing continue birth control throughout study . 7 . Subjects must willing able understand comply requirement study , apply study medication instruct , return require treatment period visit , comply therapy prohibition , able complete study . 8 . Subjects must good health , confirm medical history physical exam , free clinically significant disease/condition , plaque psoriasis , might interfere study evaluation . 9 . Subjects must willing limit sun exposure overall . Subjects prohibit sunbathe intentional tanning intense sun exposure include use tan booths/lights artificial UV light source throughout study . 1 . Female subject pregnant , nursing , plan pregnancy within study participation period . 2 . Subjects current diagnosis guttate , pustular , inverse , exfoliative , erythrodermic psoriasis . 3 . Subjects history psoriasis unresponsive topical treatment . 4 . Subjects history disorder may interfere evaluation plaque psoriasis ( e.g. , atopic dermatitis , contact dermatitis , tinea corporis , cutaneous lymphoma , etc. ) . 5 . Presence pigmentation , extensive scarring , pigmented lesion treatment area , could interfere rating efficacy parameter . 6 . Subjects unstable medical disorder , lifethreatening disease , current malignancy . 7 . Subjects clinically significant ECG laboratory abnormality Screening ( determine Investigator ) . 8 . Subjects immunosuppressed . 9 . Subjects history allergy know hypersensitivity component study medication . 10 . Subjects treat systemic steroid within 4 week prior study entry . 11 . Subjects treat systemic photo antipsoriatic therapies/drugs within 4 week prior study entry include methotrexate , cyclosporine , acitretin oral retinoids , broadband narrowband UVB , PUVA , home professional tan light nonprescription UV light source , photodynamic therapy ( PDT ) , laser , mycophenalate mofetil ( MMF ) , thioguanine , hydroxyurea , sirolimus , azathioprine , 6mercaptopurine ( 6MP ) , etanercept . 12 . Subjects treat biologic therapy etanercept within 8 week prior study entry . Vaccines consider exclusionary biologic treatment . 13 . Subjects treat topical antipsoriatic ( e.g. , salicylic acid , anthralin , tar , etc. , ) topical corticosteroid medication , topical retinoids ( e.g. , tazarotene , tretinoin ) , topical Vitamin D analog ( e.g. , calcipotriene ) , topical immunosuppressant ( e.g. , tacrolimus , pimecrolimus ) within 2 week prior study entry . 14 . Subjects treat lithium , antimalarial agent , quinidine within 4 week prior study entry . 15 . Subjects receive radiation therapy and/or antineoplastic agent , take immunosuppressant medication within 3 month prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Plaque Psoriasis</keyword>
</DOC>